Harmanjit Singh1, Nipunjot Grewal2, Ekta Arora1, Harish Kumar3, Ashish Kumar Kakkar4
1Department of Pharmacology, All India Institutes of Medical Sciences (AIIMS), Jalandhar, Punjab, India.
2Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, India.
3Department of Pharmacology, PGIMER, Chandigarh, India.
4Department of Pharmacology, VMMC and Safdarjung Hospital, New Delhi, Jalandhar, Punjab, India.
DOI: 10.4103/0976-9668.175016
ABSTRACT
Inflammatory bowel disease (IBD) is the chronic inflammatory disorder of gastrointestinal tract consisting of two subtypes: Ulcerative colitis and Crohn’s disease. IBD occurs due to infiltration of leukocytes in intestinal mucosa and derangements in intestinal barrier function. One of the most important steps in pathogenesis of IBD is the interactions between integrins on the surface of leukocyte. The α4β7 integrin expressing T-cell is an important leukocyte involved in pathogenesis and represents a new drug target for the treatment of IBD. Vedolizumab is a humanized monoclonal antibody, which acts against α4β7 integrin heterodimer and blocks the interaction of α4β7 integrin with MAdCAM-1. It prevents leukocyte binding to endothelial surface and its extravasation into affected tissue. The efficacy and safety of the vedolizumab have been established in many clinical studies. It has shown promising results in various clinical studies where a greater percentage of patients as compared to a placebo achieved and maintained clinical response, clinical remission, and corticosteroid-free clinical remission. Vedolizumab has been shown to be well tolerated with slightly higher risk of infections, headache, naspharyngitis as compared to placebo. This review focuses on the potential role of vedolizumab for the treatment of IBD.
Keywords: Crohn′s disease, inflammatory bowel disease, integrins, ulcerative colitis.
